News | March 19, 2026
Strides acquires generic brands from Sandoz to boost Africa business
The initial consideration for the transaction is US$ 12 million
The initial consideration for the transaction is US$ 12 million
ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025
The approval of Cosentyx represents an important advancement for younger HS patients who have had limited treatment options
The partnership will focus on advancing fault-tolerant quantum algorithms and developing clinically relevant quantum applications
The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus
The company announced positive topline data from the Phase 3 ADorable-1 trial
The expanded program allows patients to fill prescriptions either at a local pharmacy or through home delivery via LillyDirect
AstraZeneca says the approval strengthens its push to bring immunotherapy earlier into cancer treatment, where long-term cures are possible
The framework introduces 15 consensus terms and definitions grouped across four core dimensions of skin health
The planned facility, to be built at Samsung’s Bio Campus II, is set to become a launchpad for up to 30 emerging biotech firms
Subscribe To Our Newsletter & Stay Updated
